pazopanib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiogenesis inhibitors 4118 444731-52-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • GW786034B
  • pazopanib
  • votrient
  • GW 786034
  • pazopanib hydrochloride
  • pazopanib HCl
Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, pazopanib inhibited ligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-β receptors. In vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis in a mouse model, and the growth of some human tumor xenografts in mice.
  • Molecular weight: 437.52
  • Formula: C21H23N7O2S
  • CLOGP: 3.50
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 2
  • TPSA: 119.03
  • ALOGS: -4
  • ROTB: 5

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 0.16 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.06 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 14, 2010 EMA
Oct. 19, 2009 FDA NOVARTIS PHARMS CORP

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 1074.77 44.09 454 3088 83110 2271433
Malignant neoplasm progression 800.62 44.09 226 3316 11902 2342641
Death 676.31 44.09 328 3214 81140 2273403
Fatigue 660.50 44.09 327 3215 84546 2269997
Nausea 655.11 44.09 356 3186 111833 2242710
Hypertension 634.74 44.09 230 3312 27131 2327412
Hair colour changes 528.16 44.09 88 3454 304 2354239
Vomiting 405.33 44.09 224 3318 71378 2283165
Decreased appetite 368.53 44.09 158 3384 28733 2325810
Disease progression 283.58 44.09 113 3429 16982 2337561
Alanine aminotransferase increased 219.50 44.09 89 3453 13943 2340600
Blood pressure increased 203.10 44.09 89 3453 16897 2337646
Hepatic enzyme increased 198.49 44.09 75 3467 9727 2344816
Product use in unapproved indication 195.80 44.09 77 3465 11123 2343420
Pyrexia 187.94 44.09 124 3418 53584 2300959
Asthenia 182.96 44.09 116 3426 46810 2307733
Aspartate aminotransferase increased 176.79 44.09 74 3468 12538 2342005
Dehydration 168.13 44.09 85 3457 22210 2332333
Abdominal pain 167.27 44.09 98 3444 34276 2320267
Hepatic function abnormal 165.74 44.09 58 3484 6034 2348509
Dyspnoea 158.04 44.09 130 3412 78603 2275940
Anaemia 142.89 44.09 89 3453 34703 2319840
General physical health deterioration 133.77 44.09 63 3479 14076 2340467
Headache 133.46 44.09 119 3423 80060 2274483
Drug ineffective 133.17 44.09 132 3410 101492 2253051
Weight decreased 132.93 44.09 79 3463 28292 2326251
Blood bilirubin increased 130.59 44.09 47 3495 5298 2349245
Pleural effusion 129.19 44.09 58 3484 11610 2342933
Dysgeusia 126.42 44.09 52 3490 8407 2346136
Palmar-plantar erythrodysaesthesia syndrome 125.84 44.09 43 3499 4158 2350385
Jaundice 121.79 44.09 45 3497 5463 2349080
Hypothyroidism 119.51 44.09 42 3500 4415 2350128
Hepatotoxicity 117.57 44.09 39 3503 3442 2351101
Thrombocytopenia 115.74 44.09 63 3479 19068 2335475
Malaise 111.65 44.09 92 3450 55493 2299050
Abdominal pain upper 109.90 44.09 64 3478 22036 2332507
Stomatitis 109.79 44.09 49 3493 9661 2344882
Renal cell carcinoma 107.14 44.09 26 3516 731 2353812
Platelet count decreased 103.81 44.09 55 3487 15758 2338785
Metastatic renal cell carcinoma 98.38 44.09 20 3522 241 2354302
Soft tissue sarcoma 93.63 44.09 15 3527 37 2354506
Pain 91.32 44.09 86 3456 61771 2292772
Pneumothorax 90.60 44.09 29 3513 2283 2352260
Product use issue 90.38 44.09 46 3496 12123 2342420
Transaminases increased 88.75 44.09 34 3508 4553 2349990
Posterior reversible encephalopathy syndrome 88.60 44.09 29 3513 2451 2352092
Metastases to lung 85.83 44.09 26 3516 1705 2352838
Proteinuria 84.65 44.09 29 3513 2821 2351722
Hypertensive crisis 84.21 44.09 28 3514 2485 2352058
Pulmonary embolism 83.63 44.09 50 3492 18033 2336510
Hepatocellular injury 81.83 44.09 31 3511 4024 2350519
Ejection fraction decreased 81.24 44.09 28 3514 2773 2351770
Left ventricular dysfunction 80.71 44.09 23 3519 1217 2353326
Cardiac failure 73.53 44.09 40 3502 12054 2342489
Alopecia 72.22 44.09 49 3493 21952 2332591
Hyperthyroidism 68.81 44.09 23 3519 2074 2352469
Metastases to central nervous system 68.26 44.09 23 3519 2125 2352418
Abdominal discomfort 67.30 44.09 43 3499 17413 2337130
Metastases to pancreas 63.31 44.09 11 3531 51 2354492
Gamma-glutamyltransferase increased 62.60 44.09 28 3514 5534 2349009
Ageusia 61.94 44.09 21 3521 1977 2352566
Mucosal inflammation 61.04 44.09 27 3515 5197 2349346
Renal cancer 59.81 44.09 16 3526 668 2353875
Liver disorder 58.78 44.09 28 3514 6386 2348157
Blood alkaline phosphatase increased 58.24 44.09 28 3514 6517 2348026
Febrile neutropenia 57.96 44.09 33 3509 10849 2343694
Rash 57.44 44.09 66 3476 59492 2295051
Pneumonia 56.82 44.09 60 3482 49236 2305307
Constipation 56.68 44.09 42 3500 21587 2332956
Epistaxis 55.72 44.09 31 3511 9748 2344795
Acute kidney injury 55.12 44.09 46 3496 28076 2326467
Metastases to liver 54.01 44.09 21 3521 2920 2351623
Liver function test abnormal 51.78 44.09 27 3515 7463 2347080
Renal failure 50.70 44.09 36 3506 17313 2337230
Hyperkalaemia 48.79 44.09 24 3518 5869 2348674
Ascites 46.86 44.09 23 3519 5597 2348946
Renal impairment 46.84 44.09 28 3514 10064 2344479
Neutropenia 45.87 44.09 37 3505 21511 2333032

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 1637.83 41.26 682 4170 53170 1688759
Malignant neoplasm progression 1024.52 41.26 342 4510 13816 1728113
Fatigue 985.98 41.26 473 4379 50308 1691621
Hair colour changes 916.40 41.26 162 4690 290 1741639
Death 863.76 41.26 519 4333 86924 1655005
Nausea 790.32 41.26 409 4443 50787 1691142
Decreased appetite 743.48 41.26 311 4541 23560 1718369
Hypertension 526.52 41.26 230 4622 19218 1722711
Disease progression 417.90 41.26 189 4663 17074 1724855
Vomiting 353.30 41.26 220 4632 38095 1703834
Weight decreased 342.21 41.26 180 4672 22573 1719356
Asthenia 286.53 41.26 186 4666 34484 1707445
Dysgeusia 281.42 41.26 101 4751 4948 1736981
Dyspnoea 276.49 41.26 213 4639 51846 1690083
Renal cell carcinoma 257.45 41.26 71 4781 1437 1740492
Blood pressure increased 250.87 41.26 115 4737 10638 1731291
Metastases to lung 247.02 41.26 69 4783 1466 1740463
Renal cancer 236.32 41.26 62 4790 1029 1740900
Drug ineffective 230.49 41.26 209 4643 63592 1678337
Palmar-plantar erythrodysaesthesia syndrome 206.04 41.26 73 4779 3434 1738495
Hepatic enzyme increased 196.78 41.26 84 4768 6537 1735392
Alanine aminotransferase increased 194.99 41.26 101 4751 12177 1729752
General physical health deterioration 191.52 41.26 102 4750 13016 1728913
Product use in unapproved indication 180.38 41.26 88 4764 9334 1732595
Abdominal pain upper 176.08 41.26 91 4761 10910 1731019
Metastatic renal cell carcinoma 172.94 41.26 43 4809 568 1741361
Abdominal pain 171.28 41.26 113 4739 21377 1720552
Malaise 156.17 41.26 121 4731 29444 1712485
Dehydration 148.30 41.26 96 4756 17562 1724367
Pneumothorax 146.22 41.26 53 4799 2659 1739270
Anaemia 137.19 41.26 112 4740 29345 1712584
Hepatic function abnormal 135.08 41.26 66 4786 7008 1734921
Blood bilirubin increased 133.95 41.26 63 4789 6147 1735782
Aspartate aminotransferase increased 132.98 41.26 75 4777 10681 1731248
Jaundice 132.29 41.26 62 4790 6000 1735929
Pleural effusion 130.71 41.26 75 4777 11035 1730894
Proteinuria 125.54 41.26 48 4804 2796 1739133
Stomatitis 123.28 41.26 57 4795 5347 1736582
Headache 122.15 41.26 112 4740 34264 1707665
Pain 119.12 41.26 99 4753 26558 1715371
Pyrexia 118.15 41.26 126 4726 46274 1695655
Metastases to central nervous system 113.33 41.26 38 4814 1507 1740422
Ageusia 108.70 41.26 37 4815 1537 1740392
Hypothyroidism 108.67 41.26 42 4810 2518 1739411
Abdominal discomfort 105.95 41.26 61 4791 9020 1732909
Metastases to bone 105.11 41.26 37 4815 1701 1740228
Hepatotoxicity 101.09 41.26 42 4810 3042 1738887
Platelet count decreased 98.91 41.26 73 4779 16450 1725479
Blood creatinine increased 95.79 41.26 67 4785 13879 1728050
Cough 95.58 41.26 76 4776 19121 1722808
Thrombocytopenia 92.92 41.26 78 4774 21171 1720758
Mucosal inflammation 92.02 41.26 43 4809 4126 1737803
Renal impairment 91.25 41.26 62 4790 12252 1729677
Therapy cessation 90.41 41.26 39 4813 3100 1738829
Liver function test abnormal 87.55 41.26 46 4806 5680 1736249
Constipation 86.90 41.26 65 4787 14935 1726994
Pneumonia 86.32 41.26 107 4745 46075 1695854
Dysphonia 85.75 41.26 39 4813 3516 1738413
Liver function test increased 82.62 41.26 30 4822 1509 1740420
Nephrotic syndrome 77.50 41.26 28 4824 1388 1740541
Rash 74.41 41.26 91 4761 38602 1703327
Pain in extremity 72.96 41.26 64 4788 18408 1723521
Metastases to liver 71.34 41.26 30 4822 2237 1739692
Dizziness 71.27 41.26 84 4768 34277 1707652
Soft tissue sarcoma 71.13 41.26 13 4839 30 1741899
Neoplasm progression 69.93 41.26 33 4819 3234 1738695
Epistaxis 69.17 41.26 45 4807 8261 1733668
Renal cancer metastatic 65.87 41.26 16 4836 190 1741739
Confusional state 65.21 41.26 64 4788 21214 1720715
Blood thyroid stimulating hormone increased 64.35 41.26 20 4832 619 1741310
Gamma-glutamyltransferase increased 64.13 41.26 36 4816 5062 1736867
Renal failure 60.94 41.26 60 4792 19957 1721972
Blood alkaline phosphatase increased 60.81 41.26 35 4817 5160 1736769
Liver disorder 60.77 41.26 36 4816 5600 1736329
Haemoptysis 60.16 41.26 34 4818 4842 1737087
Dyspepsia 59.46 41.26 34 4818 4951 1736978
Back pain 58.55 41.26 54 4798 16559 1725370
Tumour pain 58.37 41.26 14 4838 157 1741772
Pancreatitis 57.54 41.26 38 4814 7149 1734780
Pulmonary embolism 57.12 41.26 48 4804 13011 1728918
Intestinal perforation 56.26 41.26 23 4829 1596 1740333
Pulmonary mass 56.16 41.26 22 4830 1365 1740564
Product use issue 56.05 41.26 40 4812 8531 1733398
Chest pain 55.67 41.26 57 4795 19857 1722072
Flatulence 54.81 41.26 27 4825 2907 1739022
Impaired healing 51.98 41.26 25 4827 2554 1739375
Blister 51.74 41.26 29 4823 4063 1737866
Arthralgia 51.35 41.26 59 4793 23385 1718544
Acute kidney injury 49.78 41.26 71 4781 34873 1707056
Skin discolouration 49.23 41.26 25 4827 2871 1739058
Hyperthyroidism 46.66 41.26 20 4832 1562 1740367
Cardiac failure 46.40 41.26 42 4810 12560 1729369
Dry skin 46.09 41.26 26 4826 3686 1738243
Second primary malignancy 43.58 41.26 17 4835 1042 1740887
Synovial sarcoma metastatic 43.50 41.26 7 4845 4 1741925
Metastases to lymph nodes 43.21 41.26 16 4836 850 1741079
Alopecia 43.15 41.26 25 4827 3728 1738201
Metastases to spine 43.06 41.26 13 4839 364 1741565
Erythema 42.16 41.26 42 4810 14146 1727783
Hepatic failure 41.96 41.26 29 4823 5874 1736055
Muscular weakness 41.39 41.26 36 4816 10213 1731716
Skin depigmentation 41.30 41.26 10 4842 117 1741812

Pharmacologic Action:

SourceCodeDescription
ATC L01XE11 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Protein kinase inhibitors
FDA EPC N0000175605 Kinase Inhibitor
FDA MoA N0000175076 Protein Kinase Inhibitors
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
FDA MoA N0000187062 Cytochrome P450 2C8 Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:50926 angiogenesis modulating agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Sarcoma of soft tissue indication 424952003
Renal cell carcinoma indication 702391001 DOID:4450
Hypocalcemia contraindication 5291005
Acute hemorrhage contraindication 8573003
Hyperbilirubinemia contraindication 14783006 DOID:2741
Myocardial infarction contraindication 22298006 DOID:5844
Proteinuria contraindication 29738008 DOID:576
Torsades de pointes contraindication 31722008
Gastrointestinal fistula contraindication 37831005
Hypertensive disorder contraindication 38341003 DOID:10763
Hypothyroidism contraindication 40930008 DOID:1459
Hypokalemia contraindication 43339004
Gastrointestinal perforation contraindication 51875005
Hepatic failure contraindication 59927004
Diarrhea contraindication 62315008
Gastrointestinal hemorrhage contraindication 74474003
Pancreatitis contraindication 75694006 DOID:4989
Prolonged QT interval contraindication 111975006
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Angina pectoris contraindication 194828000
Drug-induced hepatitis contraindication 235876009
Impaired wound healing contraindication 271618001
Cerebral hemorrhage contraindication 274100004
Pregnancy, function contraindication 289908002
Thromboembolic disorder contraindication 371039008
Surgical procedure contraindication 387713003
Cardiovascular event risk contraindication 395112001
UGT1A1*28 polymorphism contraindication 430235005
Congenital long QT syndrome contraindication 442917000
Hypertensive urgency contraindication 443482000
Acute Thromboembolic Stroke contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.3 acidic
pKa2 5.69 Basic
pKa3 1.23 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 8.74 CHEMBL CHEMBL
Fibroblast growth factor receptor 1 Kinase INHIBITOR Kd 6 CHEMBL CHEMBL
Tyrosine-protein kinase Lck Kinase INHIBITOR Kd 5.92 CHEMBL CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase INHIBITOR Kd 8.10 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR Kd 7.57 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR Kd 7.85 CHEMBL CHEMBL
Platelet-derived growth factor receptor alpha Kinase INHIBITOR Kd 8.31 CHEMBL CHEMBL
Fibroblast growth factor receptor 3 Kinase INHIBITOR Kd 6.21 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 1 Kinase INHIBITOR Kd 7.85 CHEMBL CHEMBL
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 8.70 CHEMBL CHEMBL
Tyrosine-protein kinase ITK/TSK Kinase INHIBITOR CHEMBL CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 6.24 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Kd 5.77 CHEMBL
MAP/microtubule affinity-regulating kinase 3 Kinase Kd 5.40 CHEMBL
Cyclin-G-associated kinase Kinase Kd 6.70 CHEMBL
Aurora kinase A Kinase Kd 5.15 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 6.32 CHEMBL
Tyrosine-protein kinase SYK Kinase Kd 5.33 CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase Kd 6.05 CHEMBL
Interferon-induced, double-stranded RNA-activated protein kinase Kinase Kd 5.72 CHEMBL
Cyclin-dependent kinase 11B Kinase Kd 5.68 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 6.12 CHEMBL
Serine/threonine-protein kinase B-raf Kinase Kd 6.37 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 5.80 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 6.12 CHEMBL
Dual specificity protein kinase TTK Kinase Kd 6.82 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 7.08 CHEMBL
Tyrosine-protein kinase Fer Kinase Kd 5.57 CHEMBL
Serine/threonine-protein kinase 16 Kinase Kd 6.44 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 6.54 CHEMBL
AP2-associated protein kinase 1 Kinase Kd 5.54 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 5.16 CHEMBL
Tyrosine-protein kinase Yes Kinase Kd 5.30 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 6.62 CHEMBL
Tyrosine-protein kinase HCK Kinase Kd 5.24 CHEMBL
Aurora kinase C Kinase Kd 6.12 CHEMBL
Fibroblast growth factor receptor 2 Kinase Kd 6.68 CHEMBL
Mitogen-activated protein kinase kinase kinase 10 Kinase Kd 5.68 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 5.52 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma Kinase Kd 6.55 CHEMBL
Serine/threonine-protein kinase 36 Kinase Kd 6.33 CHEMBL
BMP-2-inducible protein kinase Kinase Kd 5.06 CHEMBL
Mitogen-activated protein kinase kinase kinase 11 Kinase Kd 6.13 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 6.51 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 6.62 CHEMBL
Bone morphogenetic protein receptor type-1B Kinase Kd 6 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 5.47 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 5.23 CHEMBL
Protein-tyrosine kinase 6 Kinase Kd 5.64 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1G Kinase Kd 5.43 CHEMBL
Serine/threonine-protein kinase TAO2 Kinase Kd 5.74 CHEMBL
Serine/threonine-protein kinase Nek2 Kinase Kd 6.01 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 6.05 CHEMBL
LIM domain kinase 1 Kinase Kd 6.14 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3 Kinase Kd 5.80 CHEMBL
Cyclin-dependent kinase 16 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase Nek5 Kinase Kd 5.14 CHEMBL
Interleukin-1 receptor-associated kinase 3 Kinase Kd 6.10 CHEMBL
Proto-oncogene tyrosine-protein kinase ROS Kinase Kd 6.04 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 5.52 CHEMBL
Activin receptor type-2B Kinase Kd 5.62 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 5.59 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 7.09 CHEMBL
Mitogen-activated protein kinase 8 Kinase Kd 5.70 CHEMBL
Serine/threonine-protein kinase SIK2 Kinase Kd 5.14 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 7.35 CHEMBL
Tyrosine-protein kinase Srms Kinase Kd 5.60 CHEMBL
Mitogen-activated protein kinase kinase kinase 1 Kinase Kd 5.54 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 5.57 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 7.01 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 6.15 CHEMBL
TGF-beta receptor type-2 Kinase Kd 5.52 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 6.57 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 7.24 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 5.66 CHEMBL
Tyrosine-protein kinase Fes/Fps Kinase Kd 5.85 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 5.70 CHEMBL
Mitogen-activated protein kinase kinase kinase 9 Kinase Kd 6.54 CHEMBL
Leukocyte tyrosine kinase receptor Kinase Kd 5.17 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 6.03 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4 Kinase Kd 6.23 CHEMBL
Tyrosine-protein kinase TXK Kinase Kd 5.59 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 6 Kinase Kd 5.39 CHEMBL
LIM domain kinase 2 Kinase Kd 6.41 CHEMBL
ALK tyrosine kinase receptor Kinase Kd 5.66 CHEMBL
Receptor-interacting serine/threonine-protein kinase 1 Kinase Kd 6.59 CHEMBL
Cyclin-dependent kinase 11A Kinase Kd 5.89 CHEMBL
Serine/threonine-protein kinase RIO2 Kinase Kd 6.21 CHEMBL
Serine/threonine-protein kinase NLK Kinase Kd 5.36 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 5.57 CHEMBL
Serine/threonine-protein kinase SIK1 Kinase Kd 5.66 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 5.48 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 6.01 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 6.54 CHEMBL
Angiopoietin-1 receptor Kinase Kd 5.48 CHEMBL
Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma Kinase Kd 5.72 CHEMBL
Mitogen-activated protein kinase 10 Kinase Kd 5.72 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 6.42 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 6.13 CHEMBL
Phosphatidylinositol 4-kinase beta Kinase Kd 6.02 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 5.55 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1 Kinase Kd 5.68 CHEMBL
Fibroblast growth factor receptor 4 Kinase Kd 5.55 CHEMBL
Hepatocyte growth factor receptor Kinase Kd 5.70 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 6.43 CHEMBL

External reference:

IDSource
4029464 VUID
N0000180309 NUI
C1831796 UMLSCUI
D05380 KEGG_DRUG
33Y9ANM545 UNII
635702-64-6 SECONDARY_CAS_RN
443764004 SNOMEDCT_US
714438 RXNORM
26797 MMSL
4029464 VANDF
443763005 SNOMEDCT_US
013302 NDDF
d07499 MMSL
8681 INN_ID
CHEMBL477772 ChEMBL_ID
DB06589 DRUGBANK_ID
CHEBI:71219 CHEBI
CHEMBL1201733 ChEMBL_ID
10113978 PUBCHEM_CID
5698 IUPHAR_LIGAND_ID
C516667 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
VOTRIENT HUMAN PRESCRIPTION DRUG LABEL 1 0078-0670 TABLET, FILM COATED 200 mg ORAL NDA 19 sections